Masitinib: Phase III ongoing

AB Science said an IDMC recommended continuation of the open-label, French Phase III AB08026 trial comparing 7.5 mg/kg oral masitinib daily vs. 1,000 mg/m 2 IV dacarbazine every 3 weeks based on a fut...